Last reviewed · How we verify
Azilsartan Trimethylethanolamine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Azilsartan Trimethylethanolamine (Azilsartan Trimethylethanolamine) — Jiangsu Hansoh Pharmaceutical Co., Ltd.. Blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Azilsartan Trimethylethanolamine TARGET | Azilsartan Trimethylethanolamine | Jiangsu Hansoh Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Azilsartan Trimethylethanolamine CI watch — RSS
- Azilsartan Trimethylethanolamine CI watch — Atom
- Azilsartan Trimethylethanolamine CI watch — JSON
- Azilsartan Trimethylethanolamine alone — RSS
Cite this brief
Drug Landscape (2026). Azilsartan Trimethylethanolamine — Competitive Intelligence Brief. https://druglandscape.com/ci/azilsartan-trimethylethanolamine. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing